News from avanir pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

May 05, 2015, 09:00 ET
May 01, 2015, 09:00 ET
Avanir Pharmaceuticals, Inc.

Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition

 Legendary actor and director Danny Glover joins Avanir Pharmaceuticals, Inc. in a new PBAFacts campaign designed to educate and encourage...

Apr 15, 2015, 09:55 ET
Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals Announces Multiple Data Presentations Highlighting Its Central Nervous System (CNS) Therapeutics Franchise at the American Academy of Neurology (AAN) 2015 Annual Meeting

Avanir Pharmaceuticals, Inc. today announced that data highlighting its central nervous system (CNS) therapeutics franchise, including data from...

Jan 21, 2015, 07:30 ET
Avanir Pharmaceuticals, Inc.

Football Hall-of-Famer Barry Sanders Tackles Pseudobulbar Affect; A Little-known But Widespread Condition Caused by Brain Injury

 New research shows 99 percent of former professional football players surveyed by the Gridiron Greats Assistance Fund, Inc., have suffered a...

Dec 09, 2014, 19:20 ET
http://www.multivu.com/players/English/7266955-avanir-pharmaceuticals-pseudobulbar-affect-pba-documentary/gallery/image/a62180a1-718a-4956-ac27-9d9224620561.HR.jpg

Through Laughter and Tears Comes First-Ever Documentary about Life with PseudoBulbar Affect (PBA)

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the initiation of production of The PBA Film Project (working title), the first-ever...

Dec 05, 2014, 16:01 ET
Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals Cancels Previously Scheduled Earnings Call

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that, as a result of the entry by Avanir Pharmaceuticals into an agreement and...

Dec 02, 2014, 03:35 ET
Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals To Be Acquired By Otsuka Pharmaceutical For $3.5 Billion

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has entered into a definitive agreement with Otsuka Pharmaceutical Co.,...

Nov 26, 2014, 16:54 ET
Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete...

Nov 20, 2014, 09:00 ET
Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals to Participate in Two Conferences in December

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following...

Nov 07, 2014, 08:30 ET
Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals Announces Preliminary Feedback from the FDA on AVP-825 for the Acute Treatment of Migraine

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has issued preliminary...

Oct 30, 2014, 16:01 ET
Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals Announces Publication of Pivotal Phase III Results from AVP-825 Acute Migraine Study in the Journal "Headache"

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the publication of results from TARGET, a pivotal phase III study evaluating...

Oct 13, 2014, 16:26 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Announces Presentation of AVP-923 Phase II Results in Agitation in Patients with Alzheimer's Disease at the American Neurological Association Meeting

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that results from the Phase II study evaluating AVP-923 for the treatment of...

Oct 08, 2014, 16:15 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals to Host Investor Briefing on October 15, 2014

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) will host an Investor Relations Briefing on Wednesday, October 15, 2014 at 7:30 a.m. ET in New...

Oct 08, 2014, 08:30 ET
Sep 29, 2014, 09:15 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the closing of its previously announced public offering of 20,930,000 shares of its...

Sep 23, 2014, 22:00 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the pricing of a public offering of 18,200,000 shares of its common stock in an...

Sep 22, 2014, 16:45 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it is offering to sell $200 million of its common stock in an underwritten public...

Sep 15, 2014, 08:30 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Announces Positive Phase II Trial Results for AVP-923 in Treatment of Agitation in Patients with Alzheimer's Disease

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced positive results from its phase II clinical trial evaluating the safety and...

Sep 02, 2014, 09:00 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the Morgan...

Aug 26, 2014, 09:00 ET
Avanir Pharmaceuticals, Inc.  (PRNewsFoto/Avanir Pharmaceuticals, Inc.)

Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder

 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the enrollment of the first patient into a phase II study to evaluate the...